Medical Disclaimer: This content is for educational and informational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making any health-related decisions. If you are experiencing a medical emergency, call your local emergency services immediately.
What This Page Explains
Chronic low-grade inflammation — often termed 'inflammaging' — is a hallmark of biological aging and a contributor to age-related diseases including cardiovascular disease, type 2 diabetes, neurodegeneration, and cancer. Fisetin has been studied for its ability to modulate inflammatory biomarkers through multiple pathways, both directly (NF-κB inhibition) and indirectly (senescent cell clearance). This page reviews the evidence for fisetin's effects on specific inflammatory biomarkers and discusses what this data means for clinical application.
What Happened When 3,000 People Targeted Their Mitochondria
Real people. Real results. See how a cellular approach to energy changed everything for people just like you.
Detailed Evidence
INFLAMMATION PATHWAYS STUDIED Fisetin has been investigated for effects on several key inflammatory pathways: NF-κB signaling — fisetin inhibits the nuclear translocation of NF-κB, reducing transcription of pro-inflammatory genes including TNF-α, IL-6, IL-1β, and COX-2; SASP reduction — by clearing senescent cells (the senolytic effect), fisetin may indirectly reduce the major source of age-related inflammatory cytokine secretion; MAPK pathway — fisetin modulates p38 MAPK and JNK signaling, which are involved in inflammatory signal transduction; and eicosanoid metabolism — fisetin inhibits COX-2 and 5-LOX enzymes, potentially reducing inflammatory prostaglandin and leukotriene production. SPECIFIC BIOMARKER EVIDENCE C-Reactive Protein (CRP): In rodent models of aging and obesity, fisetin treatment reduced serum CRP levels by approximately 30–50%. No published human study has reported CRP changes with fisetin as a primary endpoint. Interleukin-6 (IL-6): In the 2018 mouse aging study, fisetin reduced IL-6 levels in adipose tissue. In cell culture, fisetin (10–50 μM) suppressed IL-6 secretion from LPS-stimulated macrophages by 40–60%. Human IL-6 data for fisetin is extremely limited. TNF-α: Similar to IL-6, fisetin reduces TNF-α in preclinical inflammatory models. In the SASP context, reduced TNF-α may be a downstream effect of senescent cell clearance rather than direct TNF-α inhibition. HUMAN ANTI-INFLAMMATORY DATA Published human data on fisetin's anti-inflammatory effects is very limited. The COVFIS trial included some inflammatory biomarker measurements, but the COVID-19 context, small sample size, and primary focus on safety make it difficult to draw anti-inflammatory conclusions. The NCT06133634 vascular function trial includes inflammatory biomarkers as secondary endpoints and may provide more informative data. COMPARISON WITH OTHER ANTI-INFLAMMATORY APPROACHES Evidence-based anti-inflammatory interventions with strong human data include: regular physical exercise (the most robust evidence), Mediterranean dietary pattern, omega-3 fatty acids, curcumin (moderate human evidence), and weight management. Fisetin's anti-inflammatory evidence is substantially weaker than all of these established approaches.
Evidence Hierarchy
Systematic Reviews & Meta-Analyses
Multiple high-quality trials combined
Randomized Controlled Trials (RCTs)
Gold standard for treatment efficacy
Observational Studies
Can show associations, not causation
Case Reports & Expert Opinion
Hypothesis-generating only
Preclinical (Lab/Animal) Studies
Should NOT be extrapolated to humans
The One Thing That Actually Changes As You Age (Hint: It's Not Your Attitude)
Your mitochondria are shrinking, mutating, and malfunctioning. But they don't have to. Science has found another way.
Study Quality Indicators
Higher Quality Indicators
- Large sample size (hundreds to thousands)
- Randomized and blinded design
- Placebo-controlled comparison
- Published in peer-reviewed journals
- Replicated in multiple studies
- Registered trial protocol before starting
Lower Quality Indicators
- Small sample size (under 100)
- No control group or blinding
- Manufacturer-funded with conflicts
- Only animal/cell studies
- Never replicated
- Published in predatory journals
Important Limitations
- • Supplement research often has methodological limitations
- • Results from one study may not generalize to all people
- • Marketing claims often exceed what research supports
- • Absence of evidence is not evidence of absence
- • Individual response to supplements varies widely
Quick Answers
Does fisetin reduce inflammation?
In cell culture and animal models, fisetin inhibits NF-κB and suppresses TNF-α, IL-6, and IL-1β. Published human anti-inflammatory data is very limited and no human trial has demonstrated clinically meaningful reductions in inflammatory biomarkers.
What inflammatory biomarkers does fisetin affect?
Preclinical studies show effects on CRP (30–50% reduction in rodents), IL-6 (40–60% suppression in cell culture), TNF-α, and COX-2. Human biomarker data is minimal.
What is inflammaging?
Inflammaging is chronic low-grade inflammation driven partly by senescent cell SASP. It contributes to age-related diseases including cardiovascular disease, diabetes, neurodegeneration, and cancer.
Is fisetin better than ibuprofen for inflammation?
No comparison exists. Ibuprofen is a well-studied NSAID with established anti-inflammatory efficacy. Fisetin's anti-inflammatory evidence is preclinical only. Do not substitute supplements for prescribed medications.
Does fisetin help with joint inflammation?
Some registered trials are investigating fisetin for osteoarthritis (senescent cell clearance in joint tissue). No published results demonstrate efficacy for joint inflammation in humans.
How does fisetin affect NF-κB?
Fisetin inhibits the nuclear translocation of NF-κB, reducing transcription of pro-inflammatory genes including TNF-α, IL-6, IL-1β, and COX-2. This has been demonstrated in cell culture models.
Can fisetin replace anti-inflammatory drugs?
No. Fisetin should never replace prescribed anti-inflammatory medications. Its anti-inflammatory evidence is preclinical and it has not been validated as a therapeutic intervention.
Does fisetin reduce CRP levels?
In rodent models of aging and obesity, fisetin reduced serum CRP by approximately 30–50%. No published human study has reported CRP changes with fisetin as a primary endpoint.
Is fisetin or curcumin better for inflammation?
Curcumin has moderate human anti-inflammatory evidence from multiple clinical trials. Fisetin's anti-inflammatory evidence is substantially weaker — preclinical only. Curcumin currently has stronger human data.
What is the SASP and how does it cause inflammation?
The SASP is a cocktail of inflammatory cytokines (IL-6, IL-8, TNF-α), proteases, and growth factors secreted by senescent cells. By clearing senescent cells, fisetin may indirectly reduce SASP-driven inflammation.
Does fisetin affect COX-2?
Yes. Fisetin inhibits COX-2 and 5-LOX enzymes in cell culture, potentially reducing inflammatory prostaglandin and leukotriene production. Human COX-2 inhibition data does not exist.
Can diet reduce inflammation as effectively as fisetin?
The Mediterranean dietary pattern has strong human evidence for reducing inflammation, far stronger than fisetin's preclinical data. A balanced anti-inflammatory diet is more evidence-based than fisetin supplementation.
Does fisetin reduce TNF-alpha?
In preclinical models, fisetin reduces TNF-α. In the SASP context, reduced TNF-α may be a downstream effect of senescent cell clearance rather than direct TNF-α inhibition.
Is chronic inflammation linked to aging?
Yes. Chronic low-grade inflammation (inflammaging) is a hallmark of biological aging, driven partly by senescent cell SASP, and contributes to multiple age-related diseases.
What is the strongest evidence for fisetin and inflammation?
The strongest evidence is the 2018 mouse study showing reduced SASP-associated cytokines (IL-6, TNF-α, MCP-1) in adipose tissue — suggesting anti-inflammatory effects secondary to senolytic clearance. All human data is limited.
Key Research Facts
Fisetin inhibits NF-κB transcription factor activity, reducing expression of TNF-α, IL-6, IL-1β, and COX-2 in cell culture models.
Moderate EvidenceKhan et al., Antioxidants & Redox Signaling — doi:10.1089/ars.2012.4901
In aged mice, fisetin reduced SASP-associated cytokines (IL-6, TNF-α, MCP-1) in adipose tissue — suggesting anti-inflammatory effects secondary to senolytic clearance.
Strong EvidenceYousefzadeh et al., EBioMedicine — doi:10.1016/j.ebiom.2018.09.015
In rodent models of aging and obesity, fisetin treatment reduced serum CRP levels by approximately 30–50%.
Moderate EvidencePreclinical literature — Multiple studies
The COVFIS trial included some inflammatory biomarker measurements but was not designed to assess anti-inflammatory efficacy.
Moderate EvidenceVerdoorn et al., JAGS — doi:10.1111/jgs.17416
Chronic low-grade inflammation (inflammaging) is now recognized as a hallmark of biological aging, driven partly by senescent cell SASP.
Strong EvidenceKirkland & Tchkonia, J Internal Medicine — doi:10.1111/joim.13141
No published human study has demonstrated clinically meaningful reductions in inflammatory biomarkers with fisetin supplementation.
Strong EvidenceLiterature review — PubMed search, 2026
Evidence-based anti-inflammatory interventions (exercise, Mediterranean diet, omega-3) have far stronger evidence than fisetin for reducing chronic inflammation.
Strong EvidenceClinical practice guidelines — Multiple systematic reviews
Fisetin's dual mechanism — direct NF-κB inhibition plus indirect SASP reduction via senolytic activity — is theoretically attractive but unconfirmed in humans.
Moderate EvidenceKhan et al. + Yousefzadeh et al. — Combined evidence
Inflammation is multi-causal — diet, exercise, sleep, stress, and body composition all contribute, making isolated supplement effects difficult to detect.
Strong EvidenceGeneral inflammation research — Clinical practice guidance
The NCT06133634 vascular function trial includes inflammatory biomarkers as secondary endpoints and may provide new human data.
Emerging EvidenceClinicalTrials.gov — NCT06133634
Citations & External Resources
ClinicalTrials.gov — Search: Fisetin
PubMed — Fisetin research
EBioMedicine — Yousefzadeh et al. 2018
NCT06133634 — Fisetin Vascular Function Trial
Antioxidants & Redox Signaling — Khan et al. 2013 (Anti-inflammatory Mechanisms)
JAGS — Verdoorn et al. 2021 (COVFIS Trial)
Dear Reader: Your Body Is Begging For This
Every symptom — the fatigue, the brain fog, the slow recovery — is your mitochondria sending an SOS. Are you listening?
Related Reading
Fisetin: The Complete Evidence-Based Guide
Fisetin & Cellular Senescence: Senolytic Evidence
Fisetin Benefits: What the Evidence Shows
References (3)
Written by
ReCellence™ Editorial Team
Health Content Specialists
Medically reviewed by
Medical Review Board
MD, PhD
Last updated: March 8, 2026
Last medical review: March 8, 2026